PP_1170x120_10-25-21

QINLOCK

AmerisourceBergen chosen by Deciphera Pharmaceuticals to support QINLOCK

AmerisourceBergen chosen by Deciphera Pharmaceuticals to support QINLOCK

VALLEY FORGE, Pa.  – AmerisourceBergen announced Monday that it has been selected by Deciphera Pharmaceuticals (Deciphera) to support QINLOCK (ripretinib). AmerisourceBergen is providing a unified commercialization approach for QINLOCK which was approved by the U.S. Food and Drug Administration (FDA) on Friday, May 15, 2020. QINLOCK is an orally administered kinase switch control inhibitor approved

Adheris Health